Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-444,767
Closed -$6.54M 8281
2025
Q3
$6.54M Sell
444,767
-1,740,238
-80% -$17.7M ﹤0.01% 3925
2025
Q2
$21.5M Buy
2,185,005
+1,555,776
+247% +$12.9M ﹤0.01% 2736
2025
Q1
$4.57M Buy
629,229
+287,278
+84% +$2.51M ﹤0.01% 3999
2024
Q4
$2.67M Sell
341,951
-58,287
-15% -$480K ﹤0.01% 4492
2024
Q3
$2.96M Buy
400,238
+107,793
+37% +$906K ﹤0.01% 4378
2024
Q2
$2.34M Sell
292,445
-520,177
-64% -$4.64M ﹤0.01% 4456
2024
Q1
$9.46M Sell
812,622
-2,165,898
-73% -$24M ﹤0.01% 3392
2023
Q4
$33.3M Buy
2,978,520
+2,378,766
+397% +$21.9M ﹤0.01% 2872
2023
Q3
$9.26M Sell
599,754
-1,047,262
-64% -$17.6M ﹤0.01% 3195
2023
Q2
$31.2M Buy
1,647,016
+34,177
+2% +$600K ﹤0.01% 2023
2023
Q1
$24.6M Buy
1,612,839
+1,507,728
+1,434% +$19.7M ﹤0.01% 2200
2022
Q4
$1.34M Sell
105,111
-27,254
-21% -$245K ﹤0.01% 4702
2022
Q3
$767K Buy
132,365
+34,006
+35% +$149K ﹤0.01% 5040
2022
Q2
$317K Buy
98,359
+28,050
+40% +$84.7K ﹤0.01% 5652
2022
Q1
$264K Buy
70,309
+31,353
+80% +$202K ﹤0.01% 5769
2021
Q4
$509K Sell
38,956
-175,428
-82% -$2.77M ﹤0.01% 5530
2021
Q3
$4.2M Sell
214,384
-16,495
-7% -$301K ﹤0.01% 3920
2021
Q2
$4.32M Sell
230,879
-107,091
-32% -$2.39M ﹤0.01% 3933
2021
Q1
$8M Sell
337,970
-98,999
-23% -$2.28M ﹤0.01% 2881
2020
Q4
$10.6M Buy
436,969
+434,563
+18,062% +$11.1M ﹤0.01% 2450
2020
Q3
$62K Sell
2,406
-38,218
-94% -$1.21M ﹤0.01% 5637
2020
Q2
$809K Buy
40,624
+32,070
+375% +$779K ﹤0.01% 4320
2020
Q1
$216K Sell
8,554
-18,988
-69% -$555K ﹤0.01% 4831
2019
Q4
$724K Buy
+27,542
New +$766K ﹤0.01% 4725

Other funds holding ETNB

Morgan Stanley's ETNB Position: Q4 2025 in Review

Morgan Stanley sold out of 89bio (ETNB) in Q4 2025, closing a stake of 444,767 shares — an estimated $6.54M sold.

Morgan Stanley first reported a position in ETNB in Q4 2019 and held it in 24 quarters. The position peaked at $33.3M in Q4 2023. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Morgan Stanley reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 444,767 89bio shares in Q4 2025, an estimated $6.54M.
  • Morgan Stanley first reported a position in 89bio in Q4 2019 and held it in 24 quarters.
  • Morgan Stanley's 89bio position peaked at $33.3M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.